The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

por Farraye, Francis A., Qazi, Taha, Kotze, Paulo G., Moore, Gregory T., Mundayat, Rajiv, Lawendy, Nervin, Sharma, Puza P., Judd, Donna T.
Publicado 2021

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

por Lichtenstein, Gary R, Bressler, Brian, Francisconi, Carlos, Vermeire, Severine, Lawendy, Nervin, Salese, Leonardo, Sawyerr, Gosford, Shi, Hongjiong, Su, Chinyu, Judd, Donna T, Jones, Thomas, Loftus, Edward V
Publicado 2022

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment...

por Sandborn, William J., Lawendy, Nervin, Danese, Silvio, Su, Chinyu, Loftus, Edward V., Hart, Ailsa, Dotan, Iris, Damião, Adérson O. M. C., Judd, Donna T., Guo, Xiang, Modesto, Irene, Wang, Wenjin, Panés, Julian
Publicado 2021